Objective: To evaluate the association between body fat mass distribution measured by bioelectrical impedanciometry (BEI) and high-grade prostate cancer (HGPC). Methods: We prospectively analyze 323 patients who underwent prostate biopsy. BEI was performed prior to biopsy. Prostate cancer (PC) was stratified according to D'Amico classification. For univariate analysis, Student t test was done. For multivariate analysis, bivariate logistic regression was performed using PSA, body mass index (BMI), percentage central body fat, percentage total body fat, and visceral fat as explicative variables for the diagnosis of HGPC. Results: PC was found in 134 patients. Thirty seven (27.2%) were HGPC. This group had higher age, PSA, and percentage central body fat (p = 0.001, p = 0.001, p = 0.04). BMI showed no association with HRPC. Age, PSA, and percentage central body fat (OR 1,123, 95% CI 1,022-1,233, p = 0.001) were independent risk factors. Conclusions: Central body fat measured by BEI could explain the association between obesity and HGPC better than BMI suggesting the use of this technique to study body fat distribution.

Keywords:
Endocrinology, Prostate cancer, Body mass index, Impedanciometry
1.
Allott EH, Masko EM, Freedland SJ: Obesity and prostate cancer: weighing the evidence. Eur Urol 2013;63:800-809.
2.
Liao C, Gao W, Cao W, et al: Associations of body composition measurements with serum lipid, glucose and insulin profile: a Chinese twin study. PLoS One 2015;10:e0140595.
3.
Alves FD, Souza GC, Biolo A, Clausell N: Comparison of two bioelectrical impedance devices and dual-energy X-ray absorptiometry to evaluate body composition in heart failure. J Hum Nutr Diet 2014;27:632-638.
4.
O'Malley RL, Taneja SS: Obesity and prostate cancer. Can J Urol 2006;13(suppl 2):11-17.
5.
Stewart A, Marfell-Jones, M, Olds T, de Ridder H: International Standards for Anthropometric Assessment. Lower Hutt, ISAK, 2011.
6.
Davies NM, Gaunt TR, Lewis SJ, et al: The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes Control 2015;26:1603-1616.
7.
Farwell WR, Lourenco C, Holmberg E, et al: The association between height and prostate cancer grade in the early stage prostate cancer cohort study. Cancer Causes Control 2011;22:1453-1459.
8.
Fowke JH, Motley SS, Concepcion RS, Penson DF, Barocas DA: Obesity, body composition, and prostate cancer. BMC Cancer 2012;12:23.
9.
Discacciati A, Orsini N, Wolk A: Body mass index and incidence of localized and advanced prostate cancer - a dose-response meta-analysis of prospective studies. Ann Oncol 2012;23:1665-1671.
10.
Freedland SJ, Bañez LL, Sun LL, Fitzsimons NJ, Moul JW: Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 2009;12:259-263.
11.
Oh JJ, Jeong SJ, Lee BK, et al: Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy. BJU Int 2013;112:E265-E271.
12.
Bhindi B, Margel D, Trottier G, et al: Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort. Urology 2014;83:81-87.
13.
Shiota M, Takeuchi A, Sugimoto M, et al: Low serum testosterone but not obesity predicts high Gleason score at biopsy diagnosed as prostate cancer in patients with serum PSA lower than 20 ng/ml. Anticancer Res 2015;35:6137-6145.
14.
Littman AJ, White E, Kristal AR: Anthropometrics and prostate cancer risk. Am J Epidemiol 2007;165:1271-1279.
15.
Kuczmarski MF, Kuczmarski RJ, Najjar M: Effects of age on validity of self-reported height, weight, and body mass index: findings from the third national health and nutrition examination survey, 1988-1994. J Am Diet Assoc 2001;101:28-34; quiz 35-36.
16.
Wright ME, Chang SC, Schatzkin A, et al: Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007;109:675-684.
17.
Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E: A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br J Cancer 2009;100:1799-1805.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.